000 02053cam a2200517 i 4500
999 _c68520
_d68520
001 18351360
005 20180301101903.0
008 141028s2014 enka b 001 0 eng c
010 _a 2014451468
020 _a9781849738064 (hbk.)
020 _a1849738068 (hbk.)
020 _z9781782624202 (PDF)
035 _a(OCoLC)ocn872426059
040 _CTUM
050 0 0 _aRS420
_b.O77 2014
245 0 0 _aOrphan drugs and rare diseases /
_cedited by David C. Pryde, Pfizer Global Research and Development, Cambridge, UK, Michael J. Palmer, Medicinal Chemistry Consultant, UK.
260 _aCambridge
_bRoyal Society of Chemistry
_c2014
300 _axxii, 463 pages :
_billustrations (some color) ;
_c24 cm.
504 _aIncludes bibliographical references and index.
650 0 _aOrphan drugs.
650 0 _aDrug development.
650 0 _aRare diseases.
650 1 2 _aRare Diseases
_xdrug therapy.
650 2 2 _aOrphan Drug Production.
650 7 _aDrug development.
_2fast
650 7 _aOrphan drugs.
_2fast
650 7 _aRare diseases.
_2fast
650 7 _aMédicaments orphelins.
_2ram
700 1 _aPryde, David C.,
_eeditor.
700 1 _aPalmer, Michael J.,
_eeditor.
710 2 _aRoyal Society of Chemistry (Great Britain),
_eissuing body.
942 _2lcc
_cBK